RS57874B1 - Derivati 1,3-dihidroimidazol-2-tiona za upotrebu za lečenje plućne arterijske hipertenzije i oštećenja pluća - Google Patents

Derivati 1,3-dihidroimidazol-2-tiona za upotrebu za lečenje plućne arterijske hipertenzije i oštećenja pluća

Info

Publication number
RS57874B1
RS57874B1 RS20181204A RSP20181204A RS57874B1 RS 57874 B1 RS57874 B1 RS 57874B1 RS 20181204 A RS20181204 A RS 20181204A RS P20181204 A RSP20181204 A RS P20181204A RS 57874 B1 RS57874 B1 RS 57874B1
Authority
RS
Serbia
Prior art keywords
thione
compound
dihydroimidazol
aminoethyl
formula
Prior art date
Application number
RS20181204A
Other languages
English (en)
Serbian (sr)
Inventor
Da Silva Patrício Manuel Vieira Araújo Soares
Maria João Macedo Da Silva Bonifácio
Original Assignee
Bial Portela & Ca S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca S A filed Critical Bial Portela & Ca S A
Publication of RS57874B1 publication Critical patent/RS57874B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20181204A 2012-11-14 2013-11-14 Derivati 1,3-dihidroimidazol-2-tiona za upotrebu za lečenje plućne arterijske hipertenzije i oštećenja pluća RS57874B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726119P 2012-11-14 2012-11-14
EP13803292.5A EP2919780B1 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
PCT/PT2013/000065 WO2014077715A1 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Publications (1)

Publication Number Publication Date
RS57874B1 true RS57874B1 (sr) 2018-12-31

Family

ID=49759506

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20181204A RS57874B1 (sr) 2012-11-14 2013-11-14 Derivati 1,3-dihidroimidazol-2-tiona za upotrebu za lečenje plućne arterijske hipertenzije i oštećenja pluća

Country Status (23)

Country Link
US (3) US9604970B2 (cg-RX-API-DMAC7.html)
EP (1) EP2919780B1 (cg-RX-API-DMAC7.html)
JP (1) JP6373275B2 (cg-RX-API-DMAC7.html)
KR (1) KR102259938B1 (cg-RX-API-DMAC7.html)
CN (1) CN105025895B (cg-RX-API-DMAC7.html)
AU (1) AU2013345494B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015010969B1 (cg-RX-API-DMAC7.html)
CA (1) CA2890920C (cg-RX-API-DMAC7.html)
CY (1) CY1120953T1 (cg-RX-API-DMAC7.html)
DK (1) DK2919780T3 (cg-RX-API-DMAC7.html)
ES (1) ES2693025T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181651T1 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN04089A (cg-RX-API-DMAC7.html)
LT (1) LT2919780T (cg-RX-API-DMAC7.html)
MX (1) MX355422B (cg-RX-API-DMAC7.html)
PL (1) PL2919780T3 (cg-RX-API-DMAC7.html)
PT (1) PT2919780T (cg-RX-API-DMAC7.html)
RS (1) RS57874B1 (cg-RX-API-DMAC7.html)
RU (1) RU2718055C2 (cg-RX-API-DMAC7.html)
SI (1) SI2919780T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800560T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815850T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014077715A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6373275B2 (ja) 2012-11-14 2018-08-15 バイアル−ポルテラ アンド シーエー，エス．エー． 肺動脈高血圧症及び肺障害の治療に使用するための１，３‐ジヒドロイミダゾール‐２‐チオン誘導体
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera
CN118598820B (zh) * 2024-02-06 2025-07-08 石家庄四药有限公司 一种二苯基三嗪类化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623107B2 (ja) * 1990-11-16 1994-03-30 帝人株式会社 プロスタサイクリン類を有効成分とする薬学的組成物
DK0757677T3 (da) * 1994-04-26 2003-10-13 Roche Palo Alto Llc Benzocyclohexylimidazolthionderivater
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US7125904B2 (en) 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
GB0600709D0 (en) * 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
GB0700635D0 (en) * 2007-01-12 2007-02-21 Portela & Ca Sa Therapy
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
WO2009072915A1 (en) * 2007-12-05 2009-06-11 Bial - Portela & Ca., S.A. New salts and crystal forms
BRPI0821970A2 (pt) * 2008-01-03 2015-06-23 Biomarin Pharm Inc Análogos de pterina para tratamento de condição responsiva a bh4
AR070841A1 (es) * 2008-03-13 2010-05-05 Bial Portela & Ca Sa Proceso de hidrogenacion catalitica asimetrica
AR071632A1 (es) * 2008-05-06 2010-06-30 Bial Portela & Ca Sa Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa"
DE102008054205A1 (de) * 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie
ES2632351T3 (es) * 2010-12-22 2017-09-12 Bial-Portela & Ca, S.A. Formas cristalinas y procedimientos para su preparación
JP6373275B2 (ja) 2012-11-14 2018-08-15 バイアル−ポルテラ アンド シーエー，エス．エー． 肺動脈高血圧症及び肺障害の治療に使用するための１，３‐ジヒドロイミダゾール‐２‐チオン誘導体

Also Published As

Publication number Publication date
RU2015120164A (ru) 2017-01-10
JP2016504286A (ja) 2016-02-12
US20170369477A1 (en) 2017-12-28
WO2014077715A1 (en) 2014-05-22
CA2890920A1 (en) 2014-05-22
AU2013345494A1 (en) 2015-05-14
JP6373275B2 (ja) 2018-08-15
SMT201800560T1 (it) 2019-01-11
EP2919780A1 (en) 2015-09-23
CN105025895A (zh) 2015-11-04
IN2015DN04089A (cg-RX-API-DMAC7.html) 2015-10-09
KR102259938B1 (ko) 2021-06-03
KR20150084022A (ko) 2015-07-21
US20190241545A1 (en) 2019-08-08
TR201815850T4 (tr) 2018-11-21
ES2693025T3 (es) 2018-12-07
RU2718055C2 (ru) 2020-03-30
EP2919780B1 (en) 2018-08-01
CA2890920C (en) 2020-12-15
HK1215393A1 (en) 2016-08-26
BR112015010969A2 (pt) 2017-08-22
SI2919780T1 (sl) 2018-12-31
CY1120953T1 (el) 2020-05-29
US9604970B2 (en) 2017-03-28
MX2015005910A (es) 2015-08-10
AU2013345494B2 (en) 2018-03-22
PT2919780T (pt) 2018-11-13
LT2919780T (lt) 2018-11-12
CN105025895B (zh) 2019-02-26
HRP20181651T1 (hr) 2018-12-14
DK2919780T3 (en) 2018-11-26
BR112015010969B1 (pt) 2020-05-26
MX355422B (es) 2018-04-18
US10308640B2 (en) 2019-06-04
PL2919780T3 (pl) 2019-01-31
US20150299172A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
JP3883205B2 (ja) アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
US12144811B2 (en) Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases
CA2904447C (en) Therapy for complications of diabetes
CA2439920A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US20190241545A1 (en) 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury
AU2002336267A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
AU716519B2 (en) Method of treating renal disease using an ace inhibitor and an A II antagonist
AU754852B2 (en) Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
CA2360691A1 (en) Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
US20040116510A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
HK1215393B (en) 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
HK40036978A (en) Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases